Quest Diagnostics Incorporated

Quest Diagnostics Incorporated Earnings Recaps

DGX Health Care 3 recaps
Next earnings: February 9, 2027 (estimated) · full calendar
Q3 2026 Oct 25, 2026

Quest reported 10% revenue growth and raised its full-year revenue and EPS guidance; with the stock up 1.8%, the reaction was modest rather than a clear endorsement. The transcript cites broad channel growth and productivity gains, though the excerpt does not provide the revised guidance figures.

Key takeaways
  • Revenue grew 10% and adjusted EPS increased more than 15% in the quarter.
  • Physician-channel revenue grew at a high-single-digit rate; hospital revenue grew by double digits, while reference testing revenue was up mid-single digits.
  • Quest expects consumer-health growth to exceed 30% for the full year and plans to launch Apple Health app lab ordering later this year.
  • Key advanced diagnostic tests, including in cardiometabolic, hormone, and Alzheimer’s disease areas, grew by double digits.
  • The company said it remains on track to deliver 3% in annual cost savings and productivity improvements through Invigora.
Q2 2026 Jul 25, 2026

The 8.6% stock gain reflects investor approval of Quest Diagnostics’ broad-based revenue growth and strong adjusted EPS increase, supported by robust demand across clinical, hospital, and consumer segments and raised full-year guidance.

Key takeaways
  • Revenues grew over 10% year-over-year, driven by physician, hospital, and consumer health demand, including collaborations with Corewell Health and Fresenius Medical Care.
  • Adjusted diluted EPS increased by more than 19%, bolstered by automation and AI in lab operations improving quality and productivity.
  • Double-digit revenue growth was noted in hospital partnerships, consumer wellness services (including new thyroid testing), and several advanced diagnostics areas such as cardiometabolic, autoimmune, brain health, and oncology.
  • The company expanded its oncology test access with New York State approval of Haystack MRD and integration with Flatiron Health’s Onco EMR platform, enabling broader commercial reach.
  • Management raised full-year guidance, signaling confidence in sustained demand driven by demographic and technological trends.
Q1 2026 Apr 21, 2026

Quest Diagnostics delivered a robust first quarter with over 9% organic revenue growth and a 13% increase in adjusted EPS, driven by broad-based demand and operational efficiencies.

Key takeaways
  • Organic revenue growth nearly entirely fueled by clinical innovations, new clinical areas like dialysis testing, and strategic collaborations.
  • Double-digit revenue growth in hospital channels, especially through lab solutions with Corewell Health, complemented by expanding partnerships and new lab openings.
  • Consumer health revenue surged, supported by strong repeat customer engagement and expanding lab insights integrated into digital health platforms.
  • Continued leadership in diagnostics for Alzheimer's and cardiometabolic markers, reflecting successful innovation such as the AD-Detect blood test and new biomarker guidelines.
  • Management raises full-year revenue and EPS guidance, reflecting confidence in sustained momentum and strategic execution.